Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant

Daniela Renzi, Francesco Marchesi, Gottardo De Angelis, Loredana Elia, Emanuela Salvatorelli, Svitlana Gumenyuk, Francesca Palombi, Francesco Pisani, Atelda Romano, Antonio Spadea, Elena Papa, Marco Canfora, William Arcese, Andrea Mengarelli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We describe the case of a patient with a Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with dasatinib plus steroids as the first-line therapy who achieved a molecular complete remission and then underwent a matched, unrelated donor allogeneic transplant. Five months after the transplant, he experienced a disease relapse with an T315I mutation, which was resistant to salvage chemotherapy. Once the details of the T315I mutation were acquired, we initiated ponatinib treatment at a standard dosage and observed a rapid decrease of minimal residual disease (MRD) at molecular assessment. The bone marrow evaluation after 2, 3, 6, 10 and 13 months was negative for MRD. After starting ponatinib, the patient experienced a skin graft-versus-host disease (GVHD), whereas no occurrence of GVHD was observed after transplant, suggesting that the efficacy of ponatinib could be related not only to the direct antileukemic effect, but also to its ability to promote an indirect graft-versus-leukemia effect. Ponatinib was well tolerated but a thyroid dysfunction mimicking a cardiovascular toxicity was observed and solved with hormonal substitutive treatment.

Original languageEnglish
Pages (from-to)58-61
Number of pages4
JournalChemotherapy
DOIs
Publication statusAccepted/In press - Sep 10 2016

Fingerprint

Graft vs Host Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Transplants
Recurrence
Mutation
Residual Neoplasm
Unrelated Donors
Thyroid Gland
Therapeutics
Bone Marrow
Steroids
Drug Therapy
Skin
ponatinib

Keywords

  • Acute lymphoblastic leukemia
  • Allogeneic transplant
  • Graft-versus-host disease
  • Graft-versus-leukemia effect
  • Philadelphia chromosome
  • Ponatinib
  • T315I mutation
  • Thyroid dysfunction

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant. / Renzi, Daniela; Marchesi, Francesco; De Angelis, Gottardo; Elia, Loredana; Salvatorelli, Emanuela; Gumenyuk, Svitlana; Palombi, Francesca; Pisani, Francesco; Romano, Atelda; Spadea, Antonio; Papa, Elena; Canfora, Marco; Arcese, William; Mengarelli, Andrea.

In: Chemotherapy, 10.09.2016, p. 58-61.

Research output: Contribution to journalArticle

Renzi, Daniela ; Marchesi, Francesco ; De Angelis, Gottardo ; Elia, Loredana ; Salvatorelli, Emanuela ; Gumenyuk, Svitlana ; Palombi, Francesca ; Pisani, Francesco ; Romano, Atelda ; Spadea, Antonio ; Papa, Elena ; Canfora, Marco ; Arcese, William ; Mengarelli, Andrea. / Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant. In: Chemotherapy. 2016 ; pp. 58-61.
@article{5a5e1a1cd6704f3a9bf1893c648723f5,
title = "Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant",
abstract = "We describe the case of a patient with a Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with dasatinib plus steroids as the first-line therapy who achieved a molecular complete remission and then underwent a matched, unrelated donor allogeneic transplant. Five months after the transplant, he experienced a disease relapse with an T315I mutation, which was resistant to salvage chemotherapy. Once the details of the T315I mutation were acquired, we initiated ponatinib treatment at a standard dosage and observed a rapid decrease of minimal residual disease (MRD) at molecular assessment. The bone marrow evaluation after 2, 3, 6, 10 and 13 months was negative for MRD. After starting ponatinib, the patient experienced a skin graft-versus-host disease (GVHD), whereas no occurrence of GVHD was observed after transplant, suggesting that the efficacy of ponatinib could be related not only to the direct antileukemic effect, but also to its ability to promote an indirect graft-versus-leukemia effect. Ponatinib was well tolerated but a thyroid dysfunction mimicking a cardiovascular toxicity was observed and solved with hormonal substitutive treatment.",
keywords = "Acute lymphoblastic leukemia, Allogeneic transplant, Graft-versus-host disease, Graft-versus-leukemia effect, Philadelphia chromosome, Ponatinib, T315I mutation, Thyroid dysfunction",
author = "Daniela Renzi and Francesco Marchesi and {De Angelis}, Gottardo and Loredana Elia and Emanuela Salvatorelli and Svitlana Gumenyuk and Francesca Palombi and Francesco Pisani and Atelda Romano and Antonio Spadea and Elena Papa and Marco Canfora and William Arcese and Andrea Mengarelli",
note = "Bisogna inserire Marchesi F.",
year = "2016",
month = "9",
day = "10",
doi = "10.1159/000448750",
language = "English",
pages = "58--61",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant

AU - Renzi, Daniela

AU - Marchesi, Francesco

AU - De Angelis, Gottardo

AU - Elia, Loredana

AU - Salvatorelli, Emanuela

AU - Gumenyuk, Svitlana

AU - Palombi, Francesca

AU - Pisani, Francesco

AU - Romano, Atelda

AU - Spadea, Antonio

AU - Papa, Elena

AU - Canfora, Marco

AU - Arcese, William

AU - Mengarelli, Andrea

N1 - Bisogna inserire Marchesi F.

PY - 2016/9/10

Y1 - 2016/9/10

N2 - We describe the case of a patient with a Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with dasatinib plus steroids as the first-line therapy who achieved a molecular complete remission and then underwent a matched, unrelated donor allogeneic transplant. Five months after the transplant, he experienced a disease relapse with an T315I mutation, which was resistant to salvage chemotherapy. Once the details of the T315I mutation were acquired, we initiated ponatinib treatment at a standard dosage and observed a rapid decrease of minimal residual disease (MRD) at molecular assessment. The bone marrow evaluation after 2, 3, 6, 10 and 13 months was negative for MRD. After starting ponatinib, the patient experienced a skin graft-versus-host disease (GVHD), whereas no occurrence of GVHD was observed after transplant, suggesting that the efficacy of ponatinib could be related not only to the direct antileukemic effect, but also to its ability to promote an indirect graft-versus-leukemia effect. Ponatinib was well tolerated but a thyroid dysfunction mimicking a cardiovascular toxicity was observed and solved with hormonal substitutive treatment.

AB - We describe the case of a patient with a Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with dasatinib plus steroids as the first-line therapy who achieved a molecular complete remission and then underwent a matched, unrelated donor allogeneic transplant. Five months after the transplant, he experienced a disease relapse with an T315I mutation, which was resistant to salvage chemotherapy. Once the details of the T315I mutation were acquired, we initiated ponatinib treatment at a standard dosage and observed a rapid decrease of minimal residual disease (MRD) at molecular assessment. The bone marrow evaluation after 2, 3, 6, 10 and 13 months was negative for MRD. After starting ponatinib, the patient experienced a skin graft-versus-host disease (GVHD), whereas no occurrence of GVHD was observed after transplant, suggesting that the efficacy of ponatinib could be related not only to the direct antileukemic effect, but also to its ability to promote an indirect graft-versus-leukemia effect. Ponatinib was well tolerated but a thyroid dysfunction mimicking a cardiovascular toxicity was observed and solved with hormonal substitutive treatment.

KW - Acute lymphoblastic leukemia

KW - Allogeneic transplant

KW - Graft-versus-host disease

KW - Graft-versus-leukemia effect

KW - Philadelphia chromosome

KW - Ponatinib

KW - T315I mutation

KW - Thyroid dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84988419025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988419025&partnerID=8YFLogxK

U2 - 10.1159/000448750

DO - 10.1159/000448750

M3 - Article

AN - SCOPUS:84988419025

SP - 58

EP - 61

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

ER -